CDC backs Novavax’s protein-based vaccine for COVID-19

Dive Temporary:

  • Advisers to the Facilities for Illness Management and Prevention on Tuesday unanimously really helpful Novavax’s COVID-19 vaccine for adults 18 and older following its emergency authorization by the Meals and Drug Administration final week. 
  • Shortly afterward, CDC Director Rochelle Walensky endorsed the advisers suggestion, paving the way in which for the shot’s market rollout. Novavax’s vaccine is the primary protein-based shot for COVID-19 cleared to be used within the U.S.
  • The two-dose vaccine provides adults one other vaccination possibility past photographs from Pfizer, Moderna and Johnson & Johnson. Novovax mentioned it’s making ready to ship doses within the close to future.

Dive Perception:

A yr and a half after authorization of the primary COVID-19 vaccine within the U.S., about 26 million to 37 million adults stay unvaccinated, in keeping with the CDC. 

Even among the many vaccinated, coronavirus variants like omicron and its derivatives proceed to be a public well being drawback. However unvaccinated individuals are extra more likely to have severe problems and are at a a lot increased danger of dying from COVID-19. 

Novavax’s shot may probably enchantment to some holdouts, because it’s primarily based on extra conventional vaccine expertise than the mRNA-based photographs from Pfizer and Moderna. Different protein vaccines embody photographs for influenza, hepatitis and whooping cough. 

Nonetheless, in keeping with surveys achieved by the CDC, unvaccinated individuals are not that in protein vaccines for COVID-19. Of these surveyed, about half mentioned they’d “in all probability or undoubtedly wouldn’t get an adjuvanted protein-based COVID-19 vaccine.” 

Well being officers consider they’ll persuade the general public that Novavax’s vaccine is one other protected possibility. But issues from the preliminary vaccine rollout nonetheless persist, together with misinformation, lack of belief within the authorities and issues of unwanted side effects. 

In medical testing, Novavax’s vaccine was strongly protecting towards COVID-19, however its efficiency towards omicron is unclear as the corporate’s research occurred earlier than that variant was prevalent. Adversarial reactions have been much like that of the opposite COVID-19 vaccines, and some circumstances of myocarditis — a sort of coronary heart irritation related in very uncommon situations with Pfizer’s and Moderna’s photographs — have been noticed in medical trials. 

As of Tuesday, the U.S. has bought 3.2 million doses of the Novavax vaccine. The vaccine, whereas much less acquainted to suppliers, could be simply saved in fridges. 

The vaccine is run in two doses, scheduled three to eight weeks aside.

Source link

Related Articles

Back to top button